An Early Phase 1 interventional study of Vitamin A and Nicotinamide in Skin Cancer and Kidney Transplant Recipients, sponsored by Rhode Island Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Rhode Island Hospital · Early Phase 1, Interventional, and Basic science
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 [niacin]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
582 studies on the registry are indexed under Skin Neoplasms; 114 are open to participants now.
This study's planned enrollment of 30 is below the median of 53 across 416 interventional studies indexed under Skin Neoplasms.
Browse Skin Neoplasms studies →Rhode Island Hospital is the lead sponsor of 187 studies on the registry; 37 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1,000 μg retinyl palmitate and 500 mg NAM twice a day
Drug: Vitamin A · Drug: Nicotinamide
Identical placebo pills twice a day
Other: Other: Placebo
1,000 μg retinyl palmitate twice a day for 6 months
500 mg NAM twice a day for 6 months
Also known as: Niacin (Vitamin B3)
Identical placebo pills twice a day
Change of Blood Vitamin A and Nicotinamide Levels
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rhode Island Hospital